Canopy Growth's Two-Speed Recovery: Operations Improve, Yet the Chart Refuses to Cooperate

Canopy Growth beats Q1 estimates and targets EU growth, but a restatement and proposed reverse split keep the stock 56% below its high.

The disconnect could hardly be starker. Canopy Growth just delivered a quarterly report that beat analyst expectations by a wide margin, narrowed its losses to a rounding error, and confirmed it is squeezing real savings out of its latest acquisition. The stock, meanwhile, sits 56 percent below its 52-week high of EUR 2.00, trading at EUR 0.885 — barely a third of the way back from the depths.

That gap between operational progress and market reality is the story investors need to grapple with right now.

A Quarter That Beat the Numbers

For the first quarter of fiscal 2027, reported on August 7, Canopy Growth posted net revenue of CAD 81.2 million — up 13 percent year over year and well ahead of the CAD 58.9 million analysts had penciled in. The per-share loss shrank to CAD 0.02 from CAD 0.14 in the same quarter a year earlier.

Cost discipline is clearly taking hold. The company has already banked CAD 8 million of the CAD 10 million in synergies targeted from its acquisition of MTL Cannabis, and management reaffirmed its goal of reaching positive adjusted EBITDA in fiscal 2027. The balance sheet, as of June 30, showed CAD 337 million in cash against CAD 211.4 million in long-term debt — room to maneuver, if not exactly a fortress.

CEO Luc Mongeau used the Canaccord Genuity growth conference on August 11 to lay out the next leg of the strategy: lifting the annual revenue run-rate in Europe from CAD 40 million to somewhere between CAD 100 million and CAD 150 million. The renewed EU-GMP certification for the Kincardine, Ontario facility on August 14 underpins that ambition — a necessary ticket for exporting medical cannabis into higher-margin international markets, a sharp contrast to the crowded and price-competitive Canadian recreational scene.

The Shadow Side: Restatement and Reverse Split

But the quarter's good news came wrapped in two pieces of uncomfortable packaging.

First, Canopy disclosed in its definitive proxy statement that certain historical financial statements for fiscal years 2024 and 2025 can no longer be relied upon, owing to a technical, non-cash error in how certain equity-linked warrants were classified. Management frames it as an accounting mechanics issue rather than an operational one, but for a company already under heightened scrutiny, it chips away at confidence in reporting quality.

Second, and arguably more significant for shareholders, comes the proposed share consolidation. Announced August 17, the reverse split — with a ratio between 1-for-5 and 1-for-15, at the board's discretion — goes to a vote at the annual meeting on September 25. A reverse split changes nothing about the underlying value of the company, but it sends an unmistakable signal: the share price has fallen far enough that listing requirements or regulatory considerations have entered the conversation.

The April Reform That Passed Canopy By

The broader sector context adds another layer of nuance. When the DEA rescheduled marijuana from Schedule I to the milder Schedule III in late April, it was hailed as a historic turning point for the US cannabis industry. For the multi-state operators, the change is genuinely consequential — they no longer fall under Section 280E of the US tax code, unlocking meaningful tax savings.

Canopy Growth, however, plays a different game. Its business is built on the Canadian recreational market and international medical sales, not the US multi-state model. The tax windfall that lifted the sector's prospects largely passes Canopy by. The April rally was hope; the substance behind it never applied to this company's core operations.

Reading the Chart

The technical picture tells a story of transition rather than turnaround. At EUR 0.885, the stock sits almost exactly on its 100-day moving average but 5.9 percent below the 200-day average of EUR 0.9406. It has climbed 18 percent off the 52-week low of EUR 0.75, removing it from the acute danger zone, yet remains far from anything resembling a trend reversal. The RSI of 57.3 points to neither overheating nor capitulation — just stasis.

Annualized volatility of roughly 48 percent underscores how jumpy the market remains with every headline out of Washington or Ottawa. The April episode demonstrated precisely that dynamic: the substance of the news mattered less than the initial euphoria it triggered.

Sector Momentum, Unevenly Distributed

The Canadian cannabis sector as a whole has been firming since August 2026, with Tilray Brands, Canopy Growth, and Village Farms all benefiting from stable domestic demand and expanding export markets. But the recovery within that trio is lopsided. Tilray is posting record revenues and improving profitability. Village Farms delivers strong sales with efficient production and solid cash flow. Canopy Growth shows revenue growth and better margins — but still losses.

That distinction is shaping the investment narrative. Canopy is participating in the sector's recovery without delivering the clean profitability that would justify a re-rating toward its former highs.

Speculation and Its Limits

Merger chatter has added another layer of intrigue. Curaleaf's CAD 272 million takeover offer for Aurora Cannabis on August 13 has fueled speculation about whether Canopy Growth might be next in the consolidation crosshairs. That speculation, however, rests on media reports rather than confirmed negotiations, and warrants a healthy dose of skepticism.

The analyst consensus, meanwhile, was trimmed 13 percent after the earnings release to CAD 2.02 — still well above the current trading level, but a sign that even the bulls are tempering their enthusiasm.

The Verdict

The combination of strong revenue growth, advancing synergies, and a credible European strategy suggests Canopy Growth is operationally turning a corner. The accounting restatement and the looming reverse split, however, are reminders that the company has not fully cleared the obstacles in its path. The recent share-price recovery is real, but it rests on momentum rather than a rebuilt fundamental foundation — and with the stock still closer to its low than its high, the market appears to be answering a pointed question with a cautious no: revenue growth without black ink is not yet enough to command a lasting premium.